NO20061791L - Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin - Google Patents

Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin

Info

Publication number
NO20061791L
NO20061791L NO20061791A NO20061791A NO20061791L NO 20061791 L NO20061791 L NO 20061791L NO 20061791 A NO20061791 A NO 20061791A NO 20061791 A NO20061791 A NO 20061791A NO 20061791 L NO20061791 L NO 20061791L
Authority
NO
Norway
Prior art keywords
phenylsulfonyl
piperazin
quinoline
polymorphic form
cns
Prior art date
Application number
NO20061791A
Other languages
English (en)
Inventor
Asa Elisabeth Gladwin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20061791L publication Critical patent/NO20061791L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet en ny forbindelse, 3-fenylsulfonyl-8-piperazin-l-yl-kinolin, fremgangsmåte for fremstilling derav, preparater inneholdende denne og dens anvendelse ved behandling av CNS og andre lidelser.
NO20061791A 2003-09-26 2006-04-24 Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin NO20061791L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322629.7A GB0322629D0 (en) 2003-09-26 2003-09-26 Novel compound
PCT/EP2004/010843 WO2005040124A1 (en) 2003-09-26 2004-09-23 A polymorphic form of 3-phenylsulfonyl -8-piperazin-1-yl-quinoline

Publications (1)

Publication Number Publication Date
NO20061791L true NO20061791L (no) 2006-04-24

Family

ID=29286934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061791A NO20061791L (no) 2003-09-26 2006-04-24 Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin

Country Status (24)

Country Link
US (1) US20070032504A1 (no)
EP (1) EP1667975B1 (no)
JP (1) JP2007506702A (no)
CN (1) CN1856471A (no)
AU (1) AU2004283805A1 (no)
BR (1) BRPI0414678A (no)
CA (1) CA2540022A1 (no)
CO (1) CO5680402A2 (no)
DE (1) DE602004010410T2 (no)
DK (1) DK1667975T3 (no)
ES (1) ES2297465T3 (no)
GB (1) GB0322629D0 (no)
HK (1) HK1094190A1 (no)
HR (1) HRP20080055T3 (no)
IL (1) IL174213A0 (no)
IS (1) IS8399A (no)
MA (1) MA28093A1 (no)
MX (1) MXPA06003375A (no)
NO (1) NO20061791L (no)
PL (1) PL1667975T3 (no)
PT (1) PT1667975E (no)
RU (1) RU2355681C2 (no)
WO (1) WO2005040124A1 (no)
ZA (1) ZA200601453B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080580A2 (en) * 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
CN1826322B (zh) 2003-07-22 2012-04-18 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
NZ542865A (en) 2003-09-18 2009-04-30 Virobay Inc Haloalkyl containing compounds as cysteine protease inhibitors
BRPI0611516A2 (pt) 2005-06-02 2010-09-14 Hoffmann La Roche 3-metanossulfonilquinolinas como realçadores ("enhancers") de gaba-b
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
WO2017202206A1 (zh) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 一种取代的喹啉化合物及其药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
WO2003080580A2 (en) * 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
MA28093A1 (fr) 2006-08-01
PL1667975T3 (pl) 2008-04-30
IL174213A0 (en) 2006-08-01
DE602004010410T2 (de) 2008-10-16
RU2355681C2 (ru) 2009-05-20
ZA200601453B (en) 2007-04-25
AU2004283805A1 (en) 2005-05-06
DK1667975T3 (da) 2008-04-14
EP1667975A1 (en) 2006-06-14
WO2005040124A1 (en) 2005-05-06
BRPI0414678A (pt) 2006-11-28
ES2297465T3 (es) 2008-05-01
RU2006114024A (ru) 2007-11-10
IS8399A (is) 2006-04-05
US20070032504A1 (en) 2007-02-08
HRP20080055T3 (en) 2008-02-29
CO5680402A2 (es) 2006-09-29
JP2007506702A (ja) 2007-03-22
HK1094190A1 (en) 2007-03-23
DE602004010410D1 (en) 2008-01-10
EP1667975B1 (en) 2007-11-28
GB0322629D0 (en) 2003-10-29
PT1667975E (pt) 2008-02-29
CA2540022A1 (en) 2005-05-06
MXPA06003375A (es) 2006-06-08
CN1856471A (zh) 2006-11-01

Similar Documents

Publication Publication Date Title
NO20061791L (no) Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
EA200801372A1 (ru) Способы получения замещенных пиримидинов
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
EA200501274A1 (ru) Пиразолы и способы их получения и применения
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
NO20006645D0 (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
SE0301368D0 (sv) Chemical compounds
NO20050738L (no) Ny fremgangsmate for syntesen av (7-metoksy-3,4-dihydro-1-naftalanyl)acetonitril og dens anvendelse i syntesen av agomelatin
NO20051146L (no) Fremgangsmate for fremstilling av mellomprodukter nyttige for fremstilling av tubulininhibitorer
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
WO2006058720A3 (en) Novel compounds for the treatment of neurological disorders
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
NO20055750L (no) Nye kjemiske forbindelser
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
GB0322510D0 (en) Novel compounds
WO2004043379A3 (en) Chemical compounds
SE0300850D0 (sv) Chemical compounds
WO2004032908A3 (en) Method of inhibiting angiogenesis
SE0200844D0 (sv) Chemical compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application